Global community listens to TAU genetic researcher at EU Conference on Hearing Loss
Jul 9, 2007 - 3:59:37 AM
Paris -- Prof. Karen Avraham, chair of the department of human molecular genetics and biochemistry at Tel Aviv Universitys Sackler School of Medicine, represented EuroHear, a consortium of 25 European, Israeli and U.K.-based research teams, at the European Union conference Hearing and Seeing: European Research to Fight Deafness and Blindness, held at Pariss College de France on July 2-3, 2007.
This fall, Prof. Avraham will visit the U.S. to address several Tel Aviv University:American Council groups on recent advances in research on hearing impairments.
Twelve-million euros have gone into funding EuroHear, in which Prof. Avraham plays a leading role. Attendees at the conference included hundreds of academic representatives as well as patient groups, who are instrumental in helping scientists understand hearing loss.
The goal of the conference was to bring researchers and clinicianswho work with both the deaf and blindtogether to discuss each others strides made in their respective fields, says Prof. Avraham, an American-Israeli geneticist, whose field of research, genomics, aims to investigate the biological mechanisms that can lead to hearing disorders.
Prof. Avrahams work demonstrates that geopolitical issues should not be allowed to hinder academic and scientific collaboration. Her laboratory at the Sackler School has taken part in discovering key genes for deafness in the Israeli and Palestinian populations, and she and her Palestinian colleague, Prof. Moien Kanaan, have helped identify 10 hearing loss genes. Together, as an example of Tel Aviv Universitys commitment to cross-cultural academic and scientific collaboration, they have become renowned for a unique multi-disciplinary approach to understanding the high incidence of genetic deafness among Palestinian children.
Most recently, Prof. Avrahams group discovered a new type of hearing impairment in Israel called OTSC4, a form with onset in early adulthood. Other landmark gene discovery research conducted by Prof. Avraham is now being used in diagnostic tests for patients.
Knowing ones genetic predisposition can certainly aid clinicians today and in the future for developing treatments and therapies to prevent further loss. One day a cure may be within reach, says Prof. Avraham, stressing the importance of international academic collaboration to achieve further breakthroughs.
European figures for hearing impairment mirror those in the U.S. Over 10% of the E.U. population suffer some kind of hearing impairment, a figure rising to 40% among those 75 and older. The costs of managing hearing loss are considerable in terms of physical, social and mental well-being, educational development and employment. Early identification of such conditions and intervention are therefore extremely important for society.
All rights reserved by RxPG Medical Solutions Private Limited ( www.rxpgnews.com )